Tag: news

COVINGTON, La., July 10, 2025 (GLOBE NEWSWIRE) -- Pool Corporation (Nasdaq: POOL) announced today that the Company will release its second quarter 2025 earnings results before the market opens on July 24, 2025, and will hold a conference call to discuss the results at 10:00 a.m. Central Time (11:00 a.m. Eastern Time) that same day. The earnings release as well as a live webcast and replay of the conference call will be available on the Company’s website at www.poolcorp.com. The conference call can also be accessed by dialing 1-888-348-8936 (domestic) or 1-412-902-4265 (international).  

ORANGE, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its second quarter 2025 financial results on Wednesday, July 30, after market close. Following the release, the company will host a conference call to review its financial results at 5 p.m. EDT.

Nasdaq compliance follows positive upward trend in Company’s Stock Price 

HHH to Host Earnings Call at 10 AM ET on August 7, 2025

CALGARY, Alberta, July 10, 2025 (GLOBE NEWSWIRE) -- Gibson Energy Inc. (TSX:GEI) (“Gibson” or the “Company”) announced today that it expects to release its 2025 second quarter financial and operating results on Monday, July 28, 2025, after the close of North American markets. The 2025 second quarter management's discussion and analysis and unaudited consolidated financial statements will be available on the Company's website at www.gibsonenergy.com and on SEDAR+ at www.sedarplus.ca.

SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Marc. R Theoret, M.D. to assume the newly created position of Senior Vice President, Regulatory Strategy, where he will focus on clinical regulatory strategy for Iovance’s pipeline. Effective immediately, Dr. Theoret will report to Dr. Raj K. Puri, M.D., Ph.D., Chief Regulatory Officer.

WALTHAM, Mass. and BOULDER, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its previously announced upsized underwritten public offering of 25,555,556 shares of its common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The public offering price was $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were sold by Cogent.